Hualan Biological Engineering

002007.SZPhase 3

Xinxiang, ChinaFounded 1992hualan.com

Hualan Biological Engineering is a prominent, vertically integrated vaccine and blood product manufacturer in China, with a significant market share in influenza vaccines. The company leverages its established production capabilities and extensive distribution network to serve the domestic public health market. Its strategic focus includes expanding its vaccine portfolio, advancing its plasma fractionation business, and pursuing international market opportunities. As a publicly traded entity, it plays a key role in China's national immunization programs and biosecurity strategy.

Market Cap

$3.9B

Founded

1992

Employees

3000-5000

Focus

Biotech

002007.SZ · Stock Price

USD 14.8110.41 (-41.28%)

Historical price data

AI Company Overview

Technology Platform

Large-scale egg-based vaccine manufacturing and human plasma fractionation, with ongoing development in cell culture-based vaccine production and conjugate vaccine technology.

Pipeline Snapshot

7 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
Inactivated influenza split vaccine	Human Influenza	Approved
ACYW135 Meningococcal Polysaccharide Vaccine + A+C Meningococcal Polysaccharide ...	Meningitis	Phase 3
Influenza split vaccine of 15 μg HA + Influenza split vaccine of 15 μg HA + Infl...	Influenza	Phase 3
Influenza Split Vaccine + Inactivated Influenza Vaccine	Influenza	Phase 3
Group ACYW135 Meningococcal Polysaccharide Vaccine	Meningitis	Phase 2

Funding History

IPOUndisclosedUndisclosedJun 15, 2004

Opportunities

Growth is driven by China's expanding National Immunization Program, the policy push for plasma product self-sufficiency, and the pediatric vaccine market upgrade from polysaccharide to conjugate vaccines.

International expansion in emerging markets presents an additional long-term opportunity.

Risk Factors

Key risks include heavy dependence on government procurement policies and pricing, vulnerability to fluctuations in plasma supply, intense competition in core markets, and concentration of revenue in the seasonal influenza vaccine franchise.

Competitive Landscape

Primary competitors are large domestic firms like China National Biotec Group (CNBG) and Walvax Biotech in vaccines, and Tiantan Biological and Shanghai RAAS in blood products. Hualan Bio differentiates through its dual-pillar business model, leading influenza vaccine scale, extensive plasma collection network, and strong government relationships.

Publications

Pipeline